Company press release
The General Meeting approved the accounts and discharged the Board of Directors and the Company’s Chief Executive Officer for the 2021 financial year. The Meeting decided that no dividend will be paid for the financial year ended
The Annual General Meeting approved the annual accounts and discharged the members of the Board of Directors and the CEO from all liability for the 2021 financial year.
The General Meeting decided that no dividend will be paid for the financial year ended
DEALING WITH THE REMUNERATION POLICY OF GOVERNING BODIES
The General Meeting adopted the updated remuneration policy.
BOARD OF DIRECTORS
The Annual General Meeting confirmed the number of members of the Board of Directors at four (4) and re-elected the current Board of Directors:
The Annual General Meeting has decided in accordance with the proposal of the Board of Directors that the monthly remuneration payable to the members of the Board of Directors elected at the Annual General Meeting for the mandate until the end of the Annual General Meeting in 2023 as follows:
€10,000per month for the Chairman of the Board of Directors; €6,000per month for the other members of the Board of Directors; €3,000per month for the Chairman of the Audit and Remuneration Committee; and €2,000per month for the other members of the Audit and Remuneration Committee.
The Annual General Meeting further resolved that approximately 50% of the aforementioned remuneration be paid in shares of the Company and approximately 50% be paid in cash, both in a single payment. The part of the compensation paid in shares will be paid either by purchasing shares on the public market, or by selling the Company’s own shares. The shares will be delivered to the directors within two (2) weeks from the day following the publication of the half-yearly report of the Company for the period from January 1, 2022 to March 31, 2022 or as soon as possible in accordance with the applicable legislation. The General Meeting also decided that the travel expenses of the members of the Board of Directors are compensated in accordance with the travel rules of the Company.
The General Assembly decided, on the proposal of the Board of Directors, that
AMENDMENT OF STATUTES
The General Meeting decided, on the proposal of the Board of Directors, to add to Articles 11 and 12 of the Articles of Association the following:
In clause 11:
“This article 11 of the articles of association ceases to apply in its entirety in the event that the shares of the company are admitted to trading on a regulated market as referred to in Chapter 2, Section 5 of the Finnish Securities Markets Act Subsequently, an obligation to notify significant holdings and voting share is determined in accordance with Chapter 9 of the Finnish Securities Markets Act.”
In clause 12:
“This article 12 of the articles of association ceases to apply in its entirety in the event that the shares of the company are admitted to trading on a regulated market as referred to in Chapter 2, Section 5 of the Finnish Securities Markets Act Thereafter, the procedure for a public offer and the obligation to make an offer are determined in accordance with Chapter 11 of the Finnish Securities Markets Act.”
In addition, the Annual General Meeting has decided that Article 7 will be amended so that the current wording “The shares of the company belong to the system of dematerialized securities after the expiry of the registration period decided by the board of directors“will be changed into form”The shares of the company belong to the dematerialized securities system“.
AUTHORIZING THE BOARD OF DIRECTORS TO RESOLVE THE BUYBACK OF THE COMPANY’S OWN SHARES
The General Meeting decided to authorize the Board of Directors to decide on the buyback of the Company’s own shares as follows:
The amount of shares to be redeemed may not exceed 7,000,000 shares which, after the issue of new shares listed on the
AUTHORIZING THE BOARD OF DIRECTORS TO RESOLVE THE DIRECTED ISSUE OF NEW SHARES AND SPECIAL RIGHTS
The Annual General Meeting resolved that the Board of Directors is authorized to decide on the issue of shares and special rights giving entitlement to shares referred to in Chapter 10, Section 1 of the Finnish Liability Companies Act limited by one or more decisions as follows:
The amount of shares to be issued pursuant to the authorization and the amount of shares issued pursuant to the authorization to issue special rights giving right to shares would not exceed 7,000,000 shares which, after issuance of new shares listed on the
The minutes of the General Meeting will be available on the website of
For more information, please contact:
+358 50 353 040
For investor relations matters, please contact:
Investor Relations Director
+46 7686 650 11
Nanoform is an innovative company promoting nanoparticle medicine. Nanoform works with pharmaceutical and biotechnology partners around the world to bring hope to patients in the development of new and improved medicines using Nanoform’s platform technologies. The Company is focused on reducing clinical attrition and improving the performance of drug molecules through its nanoforming technologies and formulation services. Nanoform’s capabilities include GMP manufacturing, and its services span the small and large molecule development space with a focus on addressing key drug solubility and bioavailability issues and enabling new drug applications. administration of drugs. Nanoform shares are listed on the Premier Segment of the Nasdaq First North Growth Market in
(c) Decision 2022. All rights reserved., sources